Recent advances in targeted strategies for triple-negative breast cancer
Abstract Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effecti...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-08-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-023-01497-3 |
| _version_ | 1797451781819596800 |
|---|---|
| author | Shuangli Zhu Yuze Wu Bin Song Ming Yi Yuheng Yan Qi Mei Kongming Wu |
| author_facet | Shuangli Zhu Yuze Wu Bin Song Ming Yi Yuheng Yan Qi Mei Kongming Wu |
| author_sort | Shuangli Zhu |
| collection | DOAJ |
| description | Abstract Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple targeted therapeutic strategies have emerged according to the specific molecules and signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody–drug conjugates. Moreover, immune checkpoint inhibitors, for example, pembrolizumab, atezolizumab, and durvalumab, are widely explored in the clinic. We summarize recent advances in targeted therapy and immunotherapy in TNBC, with the aim of serving as a reference for the development of individualized treatment of patients with TNBC in the future. |
| first_indexed | 2024-03-09T14:59:22Z |
| format | Article |
| id | doaj.art-bbdf892fdc1646c3a4877f88885ad098 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-03-09T14:59:22Z |
| publishDate | 2023-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-bbdf892fdc1646c3a4877f88885ad0982023-11-26T14:01:37ZengBMCJournal of Hematology & Oncology1756-87222023-08-0116113610.1186/s13045-023-01497-3Recent advances in targeted strategies for triple-negative breast cancerShuangli Zhu0Yuze Wu1Bin Song2Ming Yi3Yuheng Yan4Qi Mei5Kongming Wu6Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical UniversityDepartment of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical UniversityCancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical UniversityAbstract Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple targeted therapeutic strategies have emerged according to the specific molecules and signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody–drug conjugates. Moreover, immune checkpoint inhibitors, for example, pembrolizumab, atezolizumab, and durvalumab, are widely explored in the clinic. We summarize recent advances in targeted therapy and immunotherapy in TNBC, with the aim of serving as a reference for the development of individualized treatment of patients with TNBC in the future.https://doi.org/10.1186/s13045-023-01497-3Triple-negative breast cancerMolecular subtypeTargeted therapyImmunotherapy |
| spellingShingle | Shuangli Zhu Yuze Wu Bin Song Ming Yi Yuheng Yan Qi Mei Kongming Wu Recent advances in targeted strategies for triple-negative breast cancer Journal of Hematology & Oncology Triple-negative breast cancer Molecular subtype Targeted therapy Immunotherapy |
| title | Recent advances in targeted strategies for triple-negative breast cancer |
| title_full | Recent advances in targeted strategies for triple-negative breast cancer |
| title_fullStr | Recent advances in targeted strategies for triple-negative breast cancer |
| title_full_unstemmed | Recent advances in targeted strategies for triple-negative breast cancer |
| title_short | Recent advances in targeted strategies for triple-negative breast cancer |
| title_sort | recent advances in targeted strategies for triple negative breast cancer |
| topic | Triple-negative breast cancer Molecular subtype Targeted therapy Immunotherapy |
| url | https://doi.org/10.1186/s13045-023-01497-3 |
| work_keys_str_mv | AT shuanglizhu recentadvancesintargetedstrategiesfortriplenegativebreastcancer AT yuzewu recentadvancesintargetedstrategiesfortriplenegativebreastcancer AT binsong recentadvancesintargetedstrategiesfortriplenegativebreastcancer AT mingyi recentadvancesintargetedstrategiesfortriplenegativebreastcancer AT yuhengyan recentadvancesintargetedstrategiesfortriplenegativebreastcancer AT qimei recentadvancesintargetedstrategiesfortriplenegativebreastcancer AT kongmingwu recentadvancesintargetedstrategiesfortriplenegativebreastcancer |